Interferon-alpha Effects on Diurnal Hypothalamic-pituitary-adrenal Axis Activity: Relationship with Proinflammatory Cytokines and Behavior

Overview

Journal Mol Psychiatry

Specialties Molecular Biology
Psychiatry

Date 2008 Jun 4

PMID 18521089

Citations 87

Authors

C L Raison

A S Borisov

B J Woolwine

Breanne Massung

G Vogt

A H Miller

Affiliations

Soon will be listed here.

Abstract

Interferon (IFN)-alpha has been used to investigate pathways by which innate immune cytokines influence the brain and behavior. Accordingly, the impact of IFN-alpha on diurnal secretion of hypothalamic-pituitary-adrenal (HPA) axis hormones was assessed in 33 patients eligible for treatment with IFN-alpha plus ribavirin for hepatitis C. In addition, the relationship between IFN-alpha-induced HPA axis changes and proinflammatory cytokines and behavior was examined. Plasma ACTH and cortisol as well as tumor necrosis factor (TNF)-alpha, interleukin-6 and their soluble receptors, were measured hourly between 0900 and 2100 hours at baseline and following approximately 12 weeks of either no treatment (n=13) or treatment with IFN-alpha/ribavirin (n=20). Plasma IFN-alpha was also measured at each visit. Depression and fatigue were assessed using the Montgomery-Asberg depression rating scale and the multidimensional fatigue inventory. Compared to no treatment, IFN-alpha/ribavirin administration was associated with significant flattening of the diurnal ACTH and cortisol slope and increased evening plasma ACTH and cortisol concentrations. Flattening of the cortisol slope and increases in evening cortisol were correlated with increases in depression (r=0.38, P<0.05 and r=0.36, P<0.05, respectively) and fatigue (r=0.43, P<0.05 and r=0.49, P<0.01, respectively). No relationship was found between immune and HPA axis measures, although increases in plasma IFN-alpha, TNF-alpha and soluble TNF-alpha receptor2 were independently correlated with behavioral endpoints. These data indicate that chronic exposure to innate immune cytokines may contribute to the altered diurnal HPA axis activity and behavior found in medically ill individuals. However, given the lack of correlation between HPA axis and immune measures, the mechanism by which chronic cytokine exposure influences HPA axis function remains to be determined.

Citing Articles

Cognitive Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Aetiology and Potential Treatments.

Bansal A, Seton K, Brooks J, Carding S Int J Mol Sci. 2025; 26(5).

PMID: 40076522 PMC: 11899462. DOI: 10.3390/ijms26051896.

Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial.

Evon D, Lin H, Khalili M, Wahed A, Yim C, Fontana R Dig Dis Sci. 2023; 68(12):4499-4510.

PMID: 37804353 PMC: 11149619. DOI: 10.1007/s10620-023-08108-8.

Glucocorticoid Hormones as Modulators of the Kynurenine Pathway in Chronic Pain Conditions.

Jovanovic F, Jovanovic V, Knezevic N Cells. 2023; 12(8).

PMID: 37190087 PMC: 10136661. DOI: 10.3390/cells12081178.

Toll-like receptor 3 neuroimmune signaling and behavior change: A strain comparison between Lewis and Wistar rats.

Giffin K, Lovelock D, Besheer J Behav Brain Res. 2022; 438:114200.

PMID: 36334783 PMC: 10123804. DOI: 10.1016/j.bbr.2022.114200.

The Relationship between Stress, Inflammation, and Depression.

Kim I, Lee J, Park S Biomedicines. 2022; 10(8).

PMID: 36009476 PMC: 9405608. DOI: 10.3390/biomedicines10081929.

References

Maddock C, Baita A, Orru M, Sitzia R, Costa A, Muntoni E . Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol. 2004; 18(1):41-6. DOI: 10.1177/0269881104040230. View

Rosmond R, Bjorntorp P . The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. J Intern Med. 2000; 247(2):188-97. DOI: 10.1046/j.1365-2796.2000.00603.x. View

Muller H, Hammes E, Hiemke C, Hess G . Interferon-alpha-2-induced stimulation of ACTH and cortisol secretion in man. Neuroendocrinology. 1991; 54(5):499-503. DOI: 10.1159/000125944. View

Shimizu H, Ohtani K, Sato N, Nagamine T, Mori M . Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration. Endocr J. 1995; 42(4):551-6. DOI: 10.1507/endocrj.42.551. View

Pace T, Hu F, Miller A . Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun. 2006; 21(1):9-19. PMC: 1820632. DOI: 10.1016/j.bbi.2006.08.009. View

Maes M, Scharpe S, Meltzer H, Okayli G, Bosmans E, DHondt P . Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res. 1994; 54(2):143-60. DOI: 10.1016/0165-1781(94)90003-5. View

Stein K, Jacobsen P, Blanchard C, Thors C . Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage. 2004; 27(1):14-23. PMC: 2547485. DOI: 10.1016/j.jpainsymman.2003.06.003. View

Quan N, STERN E, Whiteside M, Herkenham M . Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat. J Neuroimmunol. 1999; 93(1-2):72-80. DOI: 10.1016/s0165-5728(98)00193-3. View

Schroder J, Stuber F, Gallati H, Schade F, Kremer B . Pattern of soluble TNF receptors I and II in sepsis. Infection. 1995; 23(3):143-8. DOI: 10.1007/BF01793854. View

10.

Wichers M, Koek G, Robaeys G, Praamstra A, Maes M . Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol Med. 2005; 35(3):433-41. DOI: 10.1017/s0033291704003526. View

11.

Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D . Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992; 175(2):323-9. PMC: 2119112. DOI: 10.1084/jem.175.2.323. View

12.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

13.

Friebe A, Schwarz M, Schmid-Wendtner M, Volkenandt M, Schmidt F, Horn M . Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. J Immunother. 2007; 30(3):333-7. DOI: 10.1097/01.cji.0000211346.19330.c9. View

14.

Alesci S, Martinez P, Kelkar S, Ilias I, Ronsaville D, Listwak S . Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab. 2005; 90(5):2522-30. DOI: 10.1210/jc.2004-1667. View

15.

Pariante C, Pearce B, Pisell T, Sanchez C, Po C, Su C . The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology. 1999; 140(9):4359-66. DOI: 10.1210/endo.140.9.6986. View

16.

Besedovsky H, Del Rey A . Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev. 1996; 17(1):64-102. DOI: 10.1210/edrv-17-1-64. View

17.

Willerson J, Ridker P . Inflammation as a cardiovascular risk factor. Circulation. 2004; 109(21 Suppl 1):II2-10. DOI: 10.1161/01.CIR.0000129535.04194.38. View

18.

Maddock C, Landau S, Barry K, Maulayah P, Hotopf M, Cleare A . Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry. 2005; 10(4):332-3. DOI: 10.1038/sj.mp.4001634. View

19.

Van Cauter E, Leproult R, Plat L . Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA. 2000; 284(7):861-8. DOI: 10.1001/jama.284.7.861. View

20.

Evans D, Charney D, Lewis L, Golden R, Gorman J, Krishnan K . Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005; 58(3):175-89. DOI: 10.1016/j.biopsych.2005.05.001. View